NO20076663L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20076663L
NO20076663L NO20076663A NO20076663A NO20076663L NO 20076663 L NO20076663 L NO 20076663L NO 20076663 A NO20076663 A NO 20076663A NO 20076663 A NO20076663 A NO 20076663A NO 20076663 L NO20076663 L NO 20076663L
Authority
NO
Norway
Prior art keywords
immunoglobulins
antibodies
disorders
prevention
treatment
Prior art date
Application number
NO20076663A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alan Peter Lewis
Paul A Hamblin
Farhana Hussain
Ruth Mcadam
Paul Alexander Wilson
Rabinder Kumar Prinjha
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0513766A external-priority patent/GB0513766D0/en
Priority claimed from GB0525448A external-priority patent/GB0525448D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20076663L publication Critical patent/NO20076663L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse angår antistoffer mot NOGO, farmasøytiske formuleringer inneholdende dem og anvendelse av slike antistoffer ved behandling og/eller forebygging av nevrologiske sykdommer/lidelser.
NO20076663A 2005-07-05 2007-12-28 Immunoglobuliner NO20076663L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0513766A GB0513766D0 (en) 2005-07-05 2005-07-05 Immunoglobulins
GB0525448A GB0525448D0 (en) 2005-12-14 2005-12-14 Immunoglobulins
PCT/EP2006/006535 WO2007003421A2 (en) 2005-07-05 2006-07-03 Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
NO20076663L true NO20076663L (no) 2008-02-27

Family

ID=37604821

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076663A NO20076663L (no) 2005-07-05 2007-12-28 Immunoglobuliner

Country Status (22)

Country Link
EP (1) EP1899377B1 (no)
JP (1) JP2009500363A (no)
KR (1) KR20080030960A (no)
AU (1) AU2006265276B2 (no)
BR (1) BRPI0612734A2 (no)
CA (1) CA2614076A1 (no)
CR (1) CR9623A (no)
CY (1) CY1113310T1 (no)
DK (1) DK1899377T3 (no)
EA (1) EA014291B1 (no)
ES (1) ES2391902T3 (no)
HK (1) HK1115598A1 (no)
HR (1) HRP20120851T1 (no)
IL (1) IL188282A (no)
MA (1) MA29625B1 (no)
NO (1) NO20076663L (no)
NZ (1) NZ564567A (no)
PL (1) PL1899377T3 (no)
PT (1) PT1899377E (no)
SG (1) SG162829A1 (no)
SI (1) SI1899377T1 (no)
WO (1) WO2007003421A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
DK2207808T3 (da) 2007-11-02 2013-08-05 Novartis Ag Forbedrede Nogo-A-bindingsmolekyler samt deres farmaceutiske anvendelse
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
SI3723858T1 (sl) 2018-12-21 2022-04-29 Kymab Limited Bispecifično protitelo FIXAXFX s skupno lahko verigo
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
TWI329649B (en) * 2003-12-22 2010-09-01 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
JP2009500363A (ja) 2009-01-08
NZ564567A (en) 2010-09-30
DK1899377T3 (da) 2012-11-12
IL188282A0 (en) 2008-04-13
CR9623A (es) 2008-04-10
CA2614076A1 (en) 2007-01-11
SG162829A1 (en) 2010-07-29
IL188282A (en) 2011-04-28
AU2006265276A1 (en) 2007-01-11
WO2007003421A3 (en) 2007-04-12
AU2006265276B2 (en) 2011-10-13
PT1899377E (pt) 2012-11-20
EP1899377B1 (en) 2012-08-22
BRPI0612734A2 (pt) 2010-11-30
PL1899377T3 (pl) 2013-01-31
EP1899377A2 (en) 2008-03-19
EA200702634A1 (ru) 2008-06-30
KR20080030960A (ko) 2008-04-07
MA29625B1 (fr) 2008-07-01
HK1115598A1 (en) 2008-12-05
WO2007003421A2 (en) 2007-01-11
CY1113310T1 (el) 2016-04-13
SI1899377T1 (sl) 2012-12-31
ES2391902T3 (es) 2012-11-30
HRP20120851T1 (hr) 2012-11-30
EA014291B1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
NO20062767L (no) Immunoglobuliner
NO20082699L (no) Immunoglobuliner
WO2008079246A3 (en) Cd44 antibodies
NO20076663L (no) Immunoglobuliner
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
TW200709817A (en) Platform antibody compositions
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
IL180979A (en) Isoindulin compounds and their use
EA201000424A1 (ru) Антитела к il-23
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
EA200901263A1 (ru) Конденсированный аминопиридин в качестве ингибиторов hsp90
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
NO20045323L (no) Antistoffer
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2006058869A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
DK1441723T3 (da) Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application